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Purpose or Objective: Brain tumours as many other 
neurological diseases may cause sleep problems interfering 
with the delicate mechanisms of sleep regulation. The 
presence of a disturbed sleep may have material daily 
performance effects. In growing subjects this aspect may 
determine emotional and behavioral problems. The 
prevalence of sleep disorders (SD) in children with brain 
tumours is unknown. The main aim of this study is to 
compare the prevalence of SD in children affected by brain 
tumours and treated with radiotherapy to the prevalence of 
SD in children treated only surgically. 
 
Material and Methods: A retrospective case-control study 
was performed from October 2014 to April 2015 in a Pediatric 
Department and in a Pediatric Radiotherapy Centre. "Cases" 
included patients 2 to16 years old with a diagnosis of CNS 
tumour at least 3 months after treatment conclusion (surgery 
and radiotherapy and/or chemotherapy). "Controls" were 
children 2 to 16 years old with CNS tumours treated only 
surgically. Children’s sleep quality was assessed with a 
questionnaire administered to parents (Child's Sleep Habits 
Questionnaire, CSHQ). The sleep was considered disturbed if 
at least one of the following events was present: sleep delay, 
sleep duration, sleep-related anxiety, night waking, 
parasomnias and respiratory disorders. The risk of SD was 
estimated by the Odds Ratio (OR) and their 95% confidence 
intervals (95% CI) through logistic regression models. 
 
Results: We enrolled 14 cases and 14 controls, for a total of 
28 subjects. 9 out of 14 children in “case” group were 
treated with surgery, radiotherapy and chemotherapy. Our 
results highlighted a prevalence of SD of 57.4% among cases 
and 42.9% in controls. A statistically significant difference 
between the two groups (OR= 1.78 CI: 0.40-7.94) was not 
reached. 
 
Conclusion: Cranial irradiation is required to treat many 
brain tumours in children. Some studies involving only 
children with midline tumours show that high-dose cranial 
irradiation in midline site in childhood is associated to 
objective and subjective changes in the sleep-wake rhythm in 
adulthood. Our study failed to show a statistically significant 
difference in SD between the two groups, but there is 
evidence of a greater prevalence among children treated 
with radiotherapy. Limitations of the study include the small 
number of patients involved and the lack of irradiation 
details, as dose and site. We expect that a relationship 
between cranial irradiation and SD will be statistically 
confirmed increasing the number of involved patients. We 
hope to better define the relationship with irradiation dose 
and site, as brain tumour position and consequent irradiation 
may have a role on SD development. 
 
EP-1416  
Analysis of childhood brain tumours treated with 
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Purpose or Objective: The aim of the study is to evaluated 
data from radiosurgery (RS) and fractionated stereotactic 
radiotherapy (FSRT) performed in patients from 0 to 14 years 
of age in Hospital Araújo Jorge, Goiânia, Goiás, Brazil, 
treated between 2000 to 2013. 
 
Material and Methods: The authors retrospectively assessed 
medical reports of 65 patients from 0 to 14 years of age with 
diagnosis of brain tumors and who underwent RS/FSRT from 
2000 to 2013. The analysis concerns age at diagnosis, primary 
location of the tumor, size of the tumor, risk assessment, and 
employment of either RS or FSRT. 
 
Results: From the 65 records, 42 were included in the 
analysis for having all the information desired. Of those 
patients, 46.3% were male and 69.0% were diagnosed with 
malignant tumors. 29.3% of the patients were between 0 to 6 
years, 31.7% between 7 to 10 years, and 39.0% between 11 to 
14 years of age. The most frequent histophatological 
diagnoses were medulloblastoma (19.0%), arteriovenous 
malformation (14.3%), and glioma (11.9%). As for the 
treatment, 78.5% underwent to FSRT and 21.5% underwent to 
RS. The median total radiation dose prescribed dose was 
54Gy for the FSRT and 18Gy for the RS. The most frequent 
prescription dose curves were 90% and 95%, respectively, 
whilst the conformity index for the RS varied from 1.23 to 
2.04. It resulted in 42.9% of the patients having partial 
response to the performed treatment and 78.6% not having 
distant disease progression. The overall survival was 58.1 
months for patients from 0 to 6 years, 69.3 months for those 
from 7 to 10 years, and 90.2 months for those in the 11 to 15 
years range (p=.0037). 
 
Conclusion: The results show a 13 years experience on 
treating pediatric tumors with RS/FSRT of that single 
institution. High precision conformal stereotactic techniques 
with RS/FSRT employing conservative margins than 
conventional radiotherapy in childhood tumors appears to be 
safe based on our experience. Long term prospective trials 
are required to test their real potential in sustaining local 
control and minimising treatment related acute and late 
morbidity.  
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Purpose or Objective: Survivors of childhood cancer 
generally have an increased risk of developing secondary 
cancers associated with the treatment for the first primary 
cancer. Proton therapy represents a highly effective 
treatment technique for some types of childhood cancers but 
scattered radiation from secondary neutrons is an unwanted 
by-product. 
 
Material and Methods: The ANDANTE project investigates the 
relative risk of neutrons compared to photons for 
tumorigenesis, as a function of dose and energy. The 
approach is multidisciplinary, including physical 
measurements and modeling, molecular biology, radiobiology 
and epidemiology. Based on stem cells irradiated in vitro 
with either photons or neutrons, a corresponding predicted 
model of the relative risk of cancer induction from photons or 
neutrons following pediatric radiotherapy is developed and 
tested on clinical data, leading to a proposal for a 
prospective epidemiological study to validate the relative risk 
of neutrons on the tumorigenesis in humans. The progress on 
the epidemiological aspects of this current work is reported 
here. 
 
Results: In order to validate the dose-risk model developed 
earlier in the project, a feasibility study with clinical data 
from the Loma Linda University Medical Centre (LLUMC) was 
performed. A cohort of 242 patients was constituted in 
August 2013. Those patients were treated between 1991 and 
2013, diagnosed with arteriovenous malformation (AVM) 
(n=108) or low grade astrocytoma (n=134) before the ages of 
30 years, and were followed up later. All variables for 
statistical analyses are available but data extraction has not 
been finished yet. Results of this feasibility study will provide 
a basis for the development of the prospective 
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epidemiological study, and will be used to test the validity of 
a predictive risk model based on values of neutron RBE which 
will be derived from the physics task in the ANDANTE project. 
Based on the experience from the feasibility study at LLUMC, 
a proposal for a prospective epidemiological study using 
pediatric proton therapy data collected from multiple proton 
centers world-wide is prepared. For this purpose, published 
results of epidemiological studies on second malignant 
neoplasms (SMN) after radiotherapy in childhood are 
reviewed. Up to now, 57 papers were identified from 2001 
until present with the objective to estimate the magnitude of 
the effect of radiation exposure on the occurrence of SMN. 
Furthermore, European proton therapy centers were 
contacted in order to assess the feasibility of creating a 
prospective database on pediatric patients. Five out of 
thirteen proton therapy centers already replied, showing 
great interest in preliminary participation in discussion on 
forming a future prospective study. 
 
Conclusion: This will be essential for investigating the far 
reaching goal to enhance our understanding of the link 
between radiation exposure to proton therapy and the risk of 
SMNs. 
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Purpose or Objective: To: (1) produce a descriptive study of 
Irish children referred abroad for proton therapy (PT), and 
(2) to discuss the case for PT in general.  
 
Material and Methods: A retrospective review of all children 
referred for PT before October 2015 was performed. 
Information was gathered regarding general demographics, 
diagnosis, tumour grade, other treatments, the PT referral 
timeline, relapse where relevant, side effects attributable to 
PT, current status and cost of treatment to the Irish state. 
Additionally, a review of the relevant literature was 
performed. 
 
Results: Sixteen children treated in Ireland have been 
referred abroad for PT to date, with numbers increasing 
yearly. The largest number referred was in the 0–4 year old 
group. At initial diagnosis the median age was 5.0 years. Four 
patients were referred for treatment of rhabdomyosarcoma, 
3 for craniopharyngioma, 6 for intracranial ependymoma and 
1 each for treatment of meningioma, germinoma and ATRT. 
The average cost per child has been approximately €52,000. 
Two patients suffered relapse of their disease - 1 has proven 
fatal and the other is alive with disease. Four patients have 
encountered PT-related adverse effects. The time from 
referral to treatment has improved from 11 to 6 weeks 
approx.  
 
Conclusion: Despite the fact that >100,000 patients 
worldwide have been treated with PT, the current level of 
published evidence to support superiority over conventional 
treatment remains low. Planning studies have clearly 
demonstrated superior conformality and reduced risk to 
normal tissues. It is debated that randomised control trials in 
this area would be inconsistent with the principle of clinical 
equipoise. In contrast, there is a call for level 1 evidence to 
justify such drastic changes in patient care, particularly in 
the light of recent reports of unexpected toxicities.If PT 
were more widely available, the question remains in which 
clinical situations would it be likely to show substantial 
clinical and cost benefit? As no firm conclusions can be 
derived from the literature, the answer is somewhat 
speculative. In time, careful evaluation, follow-up and 
clinical trials will likely support the argument for the 
preferential use of proton therapy in children. Our challenge 
remains: how best to use it in the meantime? 
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Purpose or Objective: In the multimodal treatment concept 
for pediatric tumors the implementation of radiotherapy with 
protons gains more and more importance due to their 
outstanding radiobiological, physical and technical 
characteristics. In particular the fact, that about 60% of the 
irradiated volume of conventional radiotherapy are not 
burdened by proton therapy, results in a considerable 
reduced incidence of side effects with lowering the negative 
impact on growth and development and a lower rate of 
secondary malignancies. The German Society for Radiation 
Oncology (DEGRO) clearly recommends preferably proton 
therapy in the treatment of pediatric patients. 
 
Material and Methods: Analysis of children and adolescents 
undergoing proton radiation therapy since start of the RPTC 
2009 (time period from Jun 2009 to Sep 2015). A highly 
complex three-dimensional electromagnetic proton beam 
control system (spot scanning) can applies the tumor dose 
only to the planned target volume and spares surrounding 
healthy tissue without significant neutron exposure to the 
whole body. There is a wide range of free variety of dose 
intensity to each spot. 
 
Results: From 06/2009 to 07/2015 a total of 82 patients were 
previously treated at the RPTC in 88 cases. The mean age at 
start of irradiation was arithmetically 7.9 years (min. 11mo.; 
max. 17y. 7mo.). These were mostly rhabdomyosarcomas 
(RMS; n = 26 [29.5%]), of which 10 were alveolar and 16 were 
embryonal RMS. In the field of central nervous system, 14 
patients with low grade gliomas [16%], 11 high grade gliomas 
[12.5%], 10 ependymomas [11%] and 2 medulloblastomas 
were treated. From 12 cases with rare tumor types, 8 were 
also localized in the CNS. 6 patients had chordoma and 
chondrosarcoma, 5 Ewing tumors and 2 rare types of soft 
tissue sarcomas. 
 
Conclusion: At the field of pediatric oncology radiotherapy 
with protons using spot scanning technology is certainly 
feasible and a highly effective treatment method with 
significantly lower toxicity of normal tissue. There is a close 
cooperation with the Children's Hospital of the Municipal 
Hospital Munich/ Hospital of Munich Technical University for 
the integration of multimodal therapy studies or to treat in 
analogy with rule-based case discussions in interdisciplinary 
tumor conferences. 
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Purpose or Objective: Despite the increasing availability of 
stereotactic ablative body radiotherapy (SABR) and 
stereotactic radiosurgery (SRS) there remains a lack of 
evidence regarding their indications and role in the 
treatment of recurrent & oligo-metastatic tumours in 
children, teenagers & young adults (TYA). 
 
Material and Methods: A retrospective review of paediatric 
and TYA patients (age ≤24 years) treated with SRS or SABR at 
The Royal Marsden Hospital from 2010 to 2015 was 
